Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The FASEB Journal

• Publication date

  2001-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1096/fj.00-0538comPMID 11481219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure

  2007cited by this paper
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

  2000cited by this paper
• Immunohistochemical Localization of cGMP-binding cGMP-specific Phosphodiesterase (PDE5) in Rat Tissues

  2000cited by this paper
• Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure.

  2000cited by this paper
• Cyclic Nucleotide Phosphodiesterase Type 5 Activity Limits Blood Flow to Hypoperfused Myocardium During Exercise

  2000cited by this paper
• Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033.

  2000cited by this paper
• beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility.

  2000cited by this paper
• Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.

  2000cited by this paper
• Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

  2000cited by this paper
• Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes.

  1999cited by this paper
• Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies.

  1999influential reference
• Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases.

  1999cited by this paper
• The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.

  1999cited by this paper
• Effects of sildenafil citrate on human hemodynamics.

  1999cited by this paper
• Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

  1999cited by this paper
• Cyclic GMP Phosphodiesterase-5: Target of Sildenafil*

  1999cited by this paper
• Regulation of cardiac beta-adrenergic response by nitric oxide.

  1999cited by this paper
• Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase.

  1999cited by this paper
• Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies.

  1999cited by this paper
• Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes.

  1999cited by this paper
• Exploring the role of the beta-adrenergic receptor kinase in cardiac disease using gene-targeted mice.

  1999cited by this paper
• Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)*

  1999cited by this paper
• Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

  1999cited by this paper
• The molecular biology of cyclic nucleotide phosphodiesterases.

  1999cited by this paper
• Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.

  1998cited by this paper
• Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene.

  1998influential reference
• The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.

  1998cited by this paper
• Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness.

  1998cited by this paper
• Phosphorylation and activation of cGMP-dependent protein kinase by Src.

  1998cited by this paper
• Novel Alternative Splice Variants of cGMP-binding cGMP-specific Phosphodiesterase*

  1998influential reference
• Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

  1998cited by this paper
• Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases*

  1998cited by this paper
• Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase*

  1998cited by this paper
• Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure.

  1998cited by this paper
• Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.

  1998cited by this paper
• BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure.

  1997cited by this paper
• Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.

  1997cited by this paper
• BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure.

  1997cited by this paper
• Exercise, training, and neutrophil function.

  1997cited by this paper
• Expression of inducible nitric oxide synthase in human heart failure.

  1997cited by this paper
• Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.

  1996cited by this paper
• Expression of inducible nitric oxide synthase in human heart failure.

  1996cited by this paper
• Myocardial contractile response to nitric oxide and cGMP.

  1996cited by this paper
• Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure.

  1996cited by this paper
• Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction.

  1995cited by this paper
• Nitric Oxide Inhibits the Positive Inotropic Response to β-Adrenergic Stimulation in Humans With Left Ventricular Dysfunction

  1995cited by this paper
• 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes.

  1994cited by this paper
• Reduced beta 1 receptor messenger RNA abundance in the failing human heart.

  1993cited by this paper
• Differential Hemodynamic Responses to Selective Inhibitors of Cyclic Nucleotide Phosphodiesterases in Conscious Rats

  1992cited by this paper
• Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing.

  1991cited by this paper
• Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

  1991influential reference
• Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

  1986cited by this paper

• Regulation, effects and monitoring of compartmented cGMP signalling in cardiomyocytes-current status.

  2025cites this paper
• Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure

  2025cites this paper
• Phosphodiesterases: Evolving Concepts and Implications for Human Therapeutics.

  2024cites this paper
• Abnormal phosphorylation / dephosphorylation and Ca2+ dysfunction in heart failure

  2024cites this paper
• Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review

  2023cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• Investigation of shared genes and regulatory mechanisms associated with coronavirus disease 2019 and ischemic stroke

  2023cites this paper
• Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts

  2022cites this paper
• Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

  2022cites this paper
• Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

  2021cites this paper
• PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca2+ Content

  2021cites this paper
• Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety

  2021cites this paper
• Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG.

  2021cites this paper
• microRNAs involved in psoriasis and cardiovascular diseases

  2021cites this paper
• A scientific compendium of the effects of sildenafil citrate on the liver, kidney and heart of male albino rats at Nnewi, South East Nigeria

  2020cites this paper
• An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases

  2020influential citation
• Phosphodiesterase expression in the normal and failing heart.

  2019cites this paper
• Modulatory effect of some selected phenolic acids on enzyme activities of purinergic signaling

  2019cites this paper
• Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction

  2019cites this paper
• Неклассические эффекты силденафила в клинической медицине: междисциплинарный подход

  2019cites this paper
• Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach

  2019cites this paper
• PDE5 inhibition improves symptom-free survival and restores transverse tubule loss and catecholamine responsiveness in heart failure

  2019cites this paper
• The Contribution of Phosphodiesterases to Cardiac Dysfunction in High Carbohydrate Diet-Induced Metabolic Syndrome Rats.

  2019cites this paper
• Role of C-type natriuretic peptide in cardiac structure and function

  2018cites this paper
• MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A

  2018cites this paper
• Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System

  2018influential citation
• Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL‐1 cardiac cell line

  2018cites this paper
• Functional Microdomains in Heart’s Pacemaker: A Step Beyond Classical Electrophysiology and Remodeling

  2018cites this paper
• Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

  2018influential citation
• Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure

  2018cites this paper
• Prevention of PKG-1&agr; Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation

  2018cites this paper
• Cyclic GMP/Protein Kinase Localized Signaling and Disease Implications

  2017cites this paper
• Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy

  2017cites this paper
• Characterising and evaluating the efficacy of metabolic therapies for the treatment of Duchenne Muscular Dystrophy

  2017cites this paper
• Novel H2S-NO hybrid molecule (ZYZ-803) promoted synergistic effects against heart failure

  2017cites this paper
• Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.

  2017cites this paper
• Microdomains in the Cardiovascular System

  2017cites this paper
• Computational Modeling of Cyclic Nucleotide Signaling Mechanisms in Cardiac Myocytes

  2017cites this paper
• A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

  2017cites this paper
• 成人先天性心疾患の心血管機能 第2報：至適血行動態を目指した左心低形成症候群の治療戦略

  2017cites this paper
• Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.

  2017cites this paper
• Nitric Oxide Regulation of Cardiovascular Physiology and Pathophysiology

  2017cites this paper
• Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men

  2017cites this paper
• Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.

  2017cites this paper
• Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.

  2016cites this paper
• Acute Myocardial Response to Stretch: What We (don't) Know

  2016cites this paper
• Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

  2016cites this paper
• New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).

  2016cites this paper
• Cyclic Nucleotide Regulation of Excitation-Contraction Coupling in Cardiac Myocytes

  2016influential citation
• Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy

  2016cites this paper
• Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts

  2016cites this paper
• Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.

  2016cites this paper
• Effects of wildtype and mutant forms of atrial natriuretic peptide on L-type Ca2+ current in mouse atrial myocytes

  2016cites this paper
• Differential expression and regulation of anti-hypertrophic genes Npr1 and Npr2 during β-adrenergic receptor activation-induced hypertrophic growth in rats.

  2016cites this paper
• Erectile Dysfunction Drugs and Protein Expression of Glutathione S-transferase and Glutathione Peroxidase in the Liver of Male Rats

  2015cites this paper
• Erectile dysfunction drugs and oxidative stress in the liver of male rats

  2015cites this paper
• PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

  2015cites this paper
• Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

  2015cites this paper
• Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.

  2015cites this paper
• Cardiac Adrenergic Nervous System and Left Ventricular Remodeling

  2015cites this paper
• Real-time relationship between PKA biochemical signal network dynamics and increased action potential firing rate in heart pacemaker cells: Kinetics of PKA activation in heart pacemaker cells.

  2015cites this paper
• Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

  2015cites this paper
• Elucidation of the signalling pathway by the erectogenic bark of 'Loozi Luna Kasiika in Zambia

  2015cites this paper
• Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF

  2015cites this paper
• Coronary microvascular dysfunction in post-infarct remodelled myocardium

  2015cites this paper
• The Emperor's New Clothes: PDE5 and the Heart

  2015cites this paper
• A Temporal Characterization of the TAC and MI models of Heart Failure in CD-1 Mice

  2014cites this paper
• Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.

  2014cites this paper
• Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice

  2014cites this paper
• The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases

  2014cites this paper
• The Roles of Phosphodiesterase (PDE) 3A and 3B as Regulators of Cardiac Function in Disease

  2014cites this paper
• Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension

  2013cites this paper
• Sildenafil and cardioprotection.

  2013cites this paper
• Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction.

  2013cites this paper
• Efeitos da inibição da fosfodiesterase-5 sobre a disfunção diastólica do ventrículo esquerdo em pacientes com hipertensão arterial resistente

  2013cites this paper
• Erectile dysfunction medication induced-changes in plasma levels of homocysteine and antioxidant enzyme activities as risk factors for cardiovascular disease

  2013cites this paper
• Comparison between the Effect of Sildenafil versus Nifedipine in the Treatment of Pulmonary Hypertention in Children

  2013cites this paper
• Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

  2013cites this paper
• Enhancement of Myocardial and Vascular Function after Phosphodiesterase-5 Inhibition in a Rat Model

  2012cites this paper
• NOVEL STRATEGIES TO IMPROVE METABOLIC PARAMETERS AND PRECONDITION DIABETIC HEARTS AGAINST ISCHEMIA/REPERFUSION INJURY

  2012cites this paper
• Sildenafil and Ventriculo-Arterial Coupling in Fontan-Palliated Patients: A Noninvasive Echocardiographic Assessment

  2012cites this paper
• Cyclic GMP-dependent signaling in cardiac myocytes.

  2012cites this paper
• Effect of Sildenafil on Heart Nitric Oxide Metabolism and Mitochondrial Function

  2012cites this paper
• Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

  2012cites this paper
• Oxidative Stress and Protein Oxidation

  2012cites this paper
• Phosphodiesterases and cyclic GMP regulation in heart muscle.

  2012cites this paper
• Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling

  2012cites this paper
• Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation : Benefits

  2012cites this paper
• Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity

  2012cites this paper
• Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

  2012cites this paper
• Pathological Cardiac Hypertrophy Alters Intracellular Targeting of PDE5 from Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling

  2012cites this paper
• Regulation of cardiovascular cellular processes by S-nitrosylation.

  2012cites this paper
• KMUP‐1 inhibits hypertension‐induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin

  2012cites this paper
• Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

  2012cites this paper
• Receptor-Mediated Hypertrophic Signaling Via Protein Kinase D and Histone Deacetylase 5 in Adult Myocytes

  2012cites this paper
• Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function

  2012cites this paper
• The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension

  2012cites this paper
• Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes

  2011cites this paper
• Phosphodiesterases and cardiac cGMP: evolving roles and controversies.

  2011cites this paper
• PHOSPHODIESTERASE-5 INHIBITION: A NOVEL STRATEGY TO IMPROVE STEM CELL THERAPY IN THE HEART

  2011cites this paper